6-K
GSK plc (GSK)
6-K
2025-02-11
For: 2025-02-11
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Emma Walmsley | ||
| b) | Position/status | Chief Executive Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | The vesting of Ordinary Shares awarded in 2020 under the Company's<br>2017 Performance Share Plan and subject to an additional vesting<br>period of two years from the normal vesting date | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £0.00 | 256,706.434 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-02-10 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Emma Walmsley | ||
| b) | Position/status | Chief Executive Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2020 under the Company's 2017 Performance<br>Share Plan and subject to an additional vesting period of two years<br>from the normal vesting date | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.5319<br><br><br>. | 120,653 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-02-10 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | |
| a) | Name | Deborah Waterhouse | ||
| b) | Position/status | CEO, ViiV Healthcare and President, GSK Global Health | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Following the vesting on 10 February 2025 of 25% of an award made<br>on 10 February 2021 under the GlaxoSmithKline Deferred Investment<br>Award Programme, Deborah Waterhouse will receive a cash payment of<br>349,569.20 less applicable tax withholding in respect of<br>23,853.238 notional Ordinary Shares. | ||
| c) | Price(s)<br>and volume(s) | Volume(s) | ||
| 23,853.238 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-02-10 | ||
| f) | Place<br>of the transaction | N/A |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Regis Simard | |
| b) | Position/status | President, Global Supply Chain | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Following the vesting on 10 February 2025 of 25% of an award made<br>on 10 February 2021 under the GlaxoSmithKline Deferred Investment<br>Award Programme, Regis Simard will receive a cash payment of<br>174,784.60 less applicable tax withholding in respect of<br>11,926.619 notional<br>Ordinary Shares. | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 11,926.619 | |||
| d) | Aggregated<br>information | N/A (single transaction) | |
| Aggregated<br>volume<br><br><br><br><br><br>Price | |||
| e) | Date<br>of the transaction | 2025-02-10 | |
| f) | Place<br>of the transaction | N/A |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Luke Miels | |
| b) | Position/status | Chief Commercial Officer | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Following the vesting on 10 February 2025 of 25% of an award made<br>on 10 February 2021 under the GlaxoSmithKline Deferred Investment<br>Award Programme, Luke Miels will receive a cash payment of<br>349,569.20 less applicable tax withholding in respect of<br>23,853.238 notional Ordinary Shares. | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 23,853.238 | |||
| d) | Aggregated<br>information | N/A (single transaction) | |
| Aggregated<br>volume<br><br><br><br><br><br>Price | |||
| e) | Date<br>of the transaction | 2025-02-10 | |
| f) | Place<br>of the transaction | N/A |
All values are in British Pounds.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: February<br>11, 2025 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |